Aastrom Biosciences to Present at Merriman Curhan Ford & Co. 3rd Annual Investor Summit
September 14 2006 - 4:31PM
PR Newswire (US)
ANN ARBOR, Mich., Sept. 14 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM) today announced that George W.
Dunbar, President and Chief Executive Officer, Gerald D. Brennan,
Jr., Vice President Administrative & Financial Operations and
Chief Financial Officer, and Elmar R. Burchardt, M.D., Ph.D., Vice
President Medical Affairs will present at the Merriman Curhan Ford
& Co. 3rd Annual Investor Summit. The conference will be held
September 18-20th at The Mark Hopkins InterContinental Hotel in San
Francisco, CA. Aastrom will present on Monday, September 18th at
10:15 a.m. (Pacific Time) or 1:15 p.m. (Eastern Time). (Logo:
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO ) A live
webcast of Aastrom's presentation can be accessed by logging onto
the web at http://www.wsw.com/webcast/mcm4/astm/. A replay of the
presentation will be archived through September 20th at the same
site. For more information about the Merriman Curhan Ford & Co.
conference, please visit http://www.merrimanco.com/. About Aastrom
Biosciences, Inc. Aastrom Biosciences, Inc. (NASDAQ:ASTM) is
developing autologous cell products for the repair or regeneration
of multiple human tissues, based on its proprietary Tissue Repair
Cell (TRC) technology. Aastrom's TRC-based products are a unique
cell mixture containing stromal, stem and progenitor cell
populations, produced outside the body from a small amount of bone
marrow taken from the patient. TRC-based products have been used in
over 225 patients, and are currently in clinical trials for bone
regeneration (long bone fractures and spine fusion) and vascular
regeneration (critical limb ischemia) applications. The Company has
reported positive interim clinical trial results for TRCs
suggesting both the clinical safety and the ability of TRCs to
induce tissue regeneration in long bone fractures and jaw bone
reconstruction. Recently, the Company's proprietary TRCs received
an Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) for use in the treatment of osteonecrosis of
the femoral head. In addition, Aastrom is developing plans for a
TRC-based therapy for cardiac regeneration. For more information,
visit Aastrom's website at http://www.aastrom.com/ . This document
contains forward-looking statements, including without limitation,
statements regarding product development objectives, market
development plans, and potential advantages and applications of
Tissue Repair Cells, which involve certain risks and uncertainties.
The forward-looking statements are also identified through use of
the words "plans," and other words of similar meaning. Actual
results may differ significantly from the expectations contained in
the forward-looking statements. Among the factors that may result
in differences are the results obtained from clinical trial
activities, regulatory approval requirements, and the availability
of resources. These and other significant factors are discussed in
greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly Cameron Associates Investor Relations Department Kevin
McGrath Aastrom Biosciences, Inc. Phone: (212) 245-4577 Phone:
(734) 930-5777 Deanne Eagle (Media) Phone: (212) 554-5463
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO
http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly, Investor Relations Department of Aastrom
Biosciences, Inc., +1-734-930-5777; or Kevin McGrath,
+1-212-245-4577, or Deanne Eagle (Media), +1-212-554-5463, both of
Cameron Associates Web site: http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024